JP2007506726A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506726A5
JP2007506726A5 JP2006527499A JP2006527499A JP2007506726A5 JP 2007506726 A5 JP2007506726 A5 JP 2007506726A5 JP 2006527499 A JP2006527499 A JP 2006527499A JP 2006527499 A JP2006527499 A JP 2006527499A JP 2007506726 A5 JP2007506726 A5 JP 2007506726A5
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
pyridyl
fluorine atoms
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006527499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506726A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002978 external-priority patent/WO2005030184A2/en
Publication of JP2007506726A publication Critical patent/JP2007506726A/ja
Publication of JP2007506726A5 publication Critical patent/JP2007506726A5/ja
Withdrawn legal-status Critical Current

Links

JP2006527499A 2003-09-25 2004-09-13 α2δ−タンパク質に対する親和性を有するアミノ酸の使用方法 Withdrawn JP2007506726A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50600303P 2003-09-25 2003-09-25
PCT/IB2004/002978 WO2005030184A2 (en) 2003-09-25 2004-09-13 Therapeutic beta aminoacids

Publications (2)

Publication Number Publication Date
JP2007506726A JP2007506726A (ja) 2007-03-22
JP2007506726A5 true JP2007506726A5 (enExample) 2007-10-18

Family

ID=34393101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527499A Withdrawn JP2007506726A (ja) 2003-09-25 2004-09-13 α2δ−タンパク質に対する親和性を有するアミノ酸の使用方法

Country Status (15)

Country Link
US (2) US7112610B2 (enExample)
EP (1) EP1670452A2 (enExample)
JP (1) JP2007506726A (enExample)
KR (1) KR100774625B1 (enExample)
CN (1) CN1856301A (enExample)
AU (1) AU2004275572A1 (enExample)
BR (1) BRPI0414798A (enExample)
CA (1) CA2539976A1 (enExample)
IL (1) IL173862A0 (enExample)
MX (1) MXPA06003381A (enExample)
NO (1) NO20061801L (enExample)
RU (2) RU2344121C2 (enExample)
TW (1) TW200511989A (enExample)
WO (1) WO2005030184A2 (enExample)
ZA (1) ZA200602450B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5974084B2 (ja) 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
SI3181567T1 (sl) 2012-09-10 2019-09-30 Principia Biopharma Inc. Spojine pirazolopirimidina, kot inhibitorji kinaze
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN106456652B (zh) 2014-02-21 2020-09-11 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR102391693B1 (ko) 2016-06-29 2022-04-29 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
CN115209899A (zh) 2019-10-14 2022-10-18 普林斯匹亚生物制药公司 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
EP4093741A1 (en) 2020-01-22 2022-11-30 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2256370T3 (es) * 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
FR2791982B1 (fr) * 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
IL157845A0 (en) * 2001-03-13 2004-03-28 Univ Kingston Anti-epileptogenic agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss

Similar Documents

Publication Publication Date Title
RU2008137379A (ru) Терапевтические бета-аминокислоты
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2013532652A5 (enExample)
JP2019505529A5 (enExample)
JP2007506726A5 (enExample)
JP2011527332A5 (enExample)
JP2014515351A5 (enExample)
JP2007508361A5 (enExample)
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
JP2013508288A5 (enExample)
JP2009542699A5 (enExample)
JP2009510044A5 (enExample)
JP2005511698A5 (enExample)
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
JP2015522589A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2015522018A5 (enExample)
JP2020506970A (ja) ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
JP2015502371A5 (enExample)
JP2005537262A5 (ja) 皮膚疾患を局所的に治療するための医薬品
RU2015135824A (ru) Бициклические соединения пиримидона в качестве ингибиторов lp-pla2
JP2014504648A5 (enExample)
JP2020510061A5 (enExample)
JP2008526950A5 (enExample)